Arthritis news. Anytime. Anywhere.

What has ACE done for you lately?

Chateau Frontenac What has ACE done for you lately?

Here’s what we’ve been up to in the new year!

In this issue of “What has ACE done for you lately” – a monthly roundup of what we have accomplished and what we are currently working on – we highlight our campaigns in the workplace, healthcare, arthritis community and research.

Live at the Canadian Rheumatology Association 70th Annual Scientific Meeting

Continue reading

Let BC PharmaCare hear “Your Voice” on tofacitinib

Stickman with megaphone calling for patient inputLet BC PharmaCare hear “Your Voice” on tofacitinib for rheumatoid arthritis

Taken orally, tofacitinib (Xeljanz®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tofacitinib for the treatment of rheumatoid arthritis (RA).

You can give input if you are a B.C. resident and have RA, a caregiver to someone with RA, or if your group represents people who live with RA.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.

It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for. Continue reading

Let BC PharmaCare hear “Your Voice” on certolizumab pegol

Megaphone GraphicLet BC PharmaCare hear “Your Voice” on certolizumab pegol for ankylosing spondylitis

The subcutaneous (under the skin) injection certolizumab pegol (Cimzia®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about certolizumab pegol for the treatment of ankylosing spondylitis (AS).

You can give input if you are a B.C. resident and have AS, a caregiver to someone with AS, or if your group represents people who live with AS.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process. Continue reading

Join Cheryl Koehn in webinar on subsequent entry biologics

Canadian Breast Cancer Network Logo

 

Cheryl Koehn, President of Arthritis Consumer Experts, will be presenting in a free webinar on subsequent entry biologics today from 7pm-8pm EST. The webinar is hosted by the Canadian Breast Cancer Network and is the first webinar of 2015 on Subsequent Entry Biologics (SEBs) and how these drugs impact breast cancer treatment.

The network is hosting the webinar in anticipation of SEBs being introduced into breast cancer treatment in about five years when Herceptin comes off patent. Because SEBs have been part of the arthritis community for a number of years now, Cheryl Koehn will explain how the arthritis community has dealt with SEBs and what the Canadian Breast Cancer Network can expect once SEBs for breast cancer enter the marketplace.

Below are the learning outcomes of the webinar:

  • What are Subsequent Entry Biologics, or SEBs?
  • Why should you care about SEBs?
  • What breast cancer specific biologics will be affected?
  • How did the arthritis community prepare for their arrival into the marketplace?
  • What can you do to stay abreast of SEB developments in breast cancer?

How to register:

To register for this FREE webinar, please CLICK HERE.

*Once you’ve registered, you should receive a confirmation email within 30 minutes. If you do not receive a confirmation email, please contact Rebecca at rwilson@cbcn.ca.

Content for this webinar was made possible through an unrestricted grant from Hoffmann-La Roche Limited.

Thank you to our friends at the CRA Annual Scientific Meeting!

Thank you NoteThank you to the rheumatologists, patients, scientists, researchers, and various medical professionals who attended the Canadian Rheumatology Association’s (CRA) 70th Annual Scientific Meeting at the Chateau Frontenac in Québec City. To everyone who followed us on our social media channels during the conference, we welcome you to continue the conversation with #CRArthritis15.

Arthritis Consumer Experts and representatives from the Canadian Arthritis Patient Alliance, the Canadian Spondylitis Association and the Arthritis Patient Advisory Board of Arthritis Research Canada were at the Arthritis Broadcast Network booth at the meeting to share the arthritis consumer perspective. Continue reading

ACE goes to Quebec City for the 2015 CRA Annual Scientific Meeting & AHPA Annual Meeting

CRA Title PageACE goes to Quebec City for the 2015 Canadian Rheumatology Association Annual Scientific Meeting & Arthritis Health Professions Association Annual Meeting

Making arthritis news: Sharing the consumer perspective through the Arthritis Broadcast Network Booth

Arthritis Consumer Experts (ACE) will be in Quebec City to attend the 2015 CRA Annual Scientific Meeting & AHPA Annual Meeting. The meetings, between Wednesday, February 4 and Saturday, February 7, bring rheumatologists and arthritis health professionals from all over Canada together to learn about and share the latest advances in arthritis research and care. The meeting also occurs during one of the world’s largest winter carnivals – the Quebec Winter Carnival. Continue reading